IACP's David G. Miller, RPh, Interviewed by Bloomberg News
Bloomberg News' Anna Edney interviewed IACP EVP/CEO David G. Miller, RPh., for today's story, "Meningitis Deaths Prompt FDA Crackdown on Drug Mixing." In the interview, Miller defends the practice of compounding and speaks to how compounding pharmacists are regulated. "Compounding pharmacists are subject to standards set by the U.S. Pharmacopeial, a non-profit standard-setting organization, not those the FDA imposes on drug manufacturers."
"The FDA should determine whether those pharmacies are conducting drug manufacturing and use its existing authorities to regulate rather than entering the field of pharmacy practice, Miller wrote March 20 in a letter to leaders of the Senate's health committee who are crafting legislation."
Miller added, "that his compounding pharmacists group will in the meantime work with state legislatures and pharmacy boards to strengthen their regulations."
Please note that the article below discloses that Sarah Sellers quoted in the story is, "a former agency compliance officer who now works for the drugmaker, Ther-Rx Corp. (0414967D), which sells a maternity medication threatened by compounding competition." Ms. Sellers works for Ther-Rx Corporation, a branded marketing subsidiary of KV Pharmaceutical, manufacturer of Makena® hydroxyprogesterone caproate injection.
Click here to view the article.